Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia

Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94

Halgren, T. A. (1996) · Journal of Computational Chemistry · doi:10.1002/(sici)1096-987x(199604)17:5/6 · Cited by 5,321 · see citing works

Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease

DeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,555 · see citing works

Thyroid Disease and the Heart

Klein, I., & Danzi, S. (2007) · Circulation · doi:10.1161/circulationaha.106.678326 · Cited by 1,324 · see citing works

Fast and selective oxidation of primary alcohols to aldehydes or to carboxylic acids and of secondary alcohols to ketones mediated by oxoammonium salts under two-phase conditions

Anelli, P. L., Biffi, C., Montanari, F., & Quici, S. (1987) · The Journal of Organic Chemistry · doi:10.1021/jo00388a038 · Cited by 786 · see citing works

Narrative review: statin-related myopathy

Joy, T. R., & Hegele, R. A. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00009 · Cited by 453 · see citing works

Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia

Ladenson, P. W., Kristensen, J. D., Ridgway, E. C., OLSSON, A. G., Carlsson, B., Klein, I. L., Baxter, J. D., & Angelin, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905633 · Cited by 337 · see citing works

Lipid Treatment Assessment Project 2

Waters, D. D., Brotons, C., Chiang, C.-W., Ferrières, J., Foody, J. M., Jukema, J. W., Santos, R. D., Verdejo, J., Messig, M., McPherson, R., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.838466 · Cited by 305 · see citing works

Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index

Erion, M. D., Cable, E. E., Ito, B. R., Jiang, H., Fujitaki, J. M., Finn, P. D., Zhang, B., Hou, J., Boyer, S. H., van Poelje, P. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702759104 · Cited by 273 · see citing works

The molecular actions of thyroid hormone in bone

Duncan Bassett, J. H., & Williams, G. R. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(03)00144-9 · Cited by 261 · see citing works

Selective thyroid hormone receptor-β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability

Grover, G. J., Mellström, K., Liu, Y., Malm, J., Li, Y., Bladh, L.-G., Sleph, P. G., Smith, M. A., George, R. J., Vennström, B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633737100 · Cited by 221 · see citing works

Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice

Johansson, L., Rudling, M. J., Scanlan, T. S., Lundåsen, T., Webb, P., Baxter, J. D., Angelin, B., & Parini, P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504379102 · Cited by 200 · see citing works

The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans

Berkenstam, A. L., Kristensen, J. D., Mellström, K., Carlsson, B., Malm, J., Rehnmark, S., Garg, N. K., Andersson, C., Rudling, M. J., Sjöberg, F., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705286104 · Cited by 191 · see citing works

Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist

Taub, R. A., Chiang, E., Chabot-Blanchet, M., Kelly, M. J., Reeves, R. A., Guertin, M., & Tardif, J. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.056 · Cited by 164 · see citing works

Structural Rearrangements in the Thyroid Hormone Receptor Hinge Domain and Their Putative Role in the Receptor Function

Nascimento, A. S., Dias, S. M. G., Nunes, F. M., Aparício, R., Ambrosio, A. L. B., Bleicher, L., Figueira, A. C. M., Santos, M. A. M., Neto, M. D. O., Fischer, H., et al. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.05.008 · Cited by 161 · see citing works

Effects of the Thyroid Hormone Receptor Agonist GC-1 on Metabolic Rate and Cholesterol in Rats and Primates: Selective Actions Relative to 3,5,3′-Triiodo- l -Thyronine

Grover, G. J., Egan, D. M., Sleph, P. G., Beehler, B. C., Chiellini, G., Nguyen, N.-H., Baxter, J. D., & Scanlan, T. S. (2004) · Endocrinology · doi:10.1210/en.2003-0973 · Cited by 161 · see citing works

Thyroid Receptor Ligands. 1. Agonist Ligands Selective for the Thyroid Receptor β1

Liu, Y., Li, Y.-L., Mellström, K., Mellin, C., Bladh, L.-G., Koehler, K., Garg, N. K., Collazo, A., Litten, C., Husman, B., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021080f · Cited by 143 · see citing works

Mechanisms and clinical implications of hepatocyte lipoapoptosis

Cazanave, S. C., & Gores, G. J. (2010) · Clinical Lipidology · doi:10.2217/clp.09.85 · Cited by 122 · see citing works

Mechanism of Thyroid-Hormone Regulated Expression of the SERCA Genes in Skeletal Muscle: Implications for Thermogenesis

Simonides, W. S., Thelen, M., van der Linden, C. G., Muller, A., & van Hardeveld, C. (2001) · Bioscience Reports · doi:10.1023/a:1013692023449 · Cited by 112 · see citing works

Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TRβ subtype-selective thyromimetics

Dow, R. L., Schneider, S. R., Paight, E. S., Hank, R. F., Chiang, P., Cornelius, P. K., Lee, E.-S., Newsome, W. P., Swick, A. G., Spitzer, J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00947-2 · Cited by 97 · see citing works

Optimizing electrostatic affinity in ligand–receptor binding: Theory, computation, and ligand properties

Kangas, E., & Tidor, B. (1998) · The Journal of Chemical Physics · doi:10.1063/1.477375 · Cited by 83 · see citing works

Clinical and Experimental Studies on the Use of 3,5-Diiodothyropropionic Acid, a Thyroid Hormone Analogue, in Heart Failure

Morkin, E., Pennock, G. D., Spooner, P. H., Bahl, J. J., & Goldman, S. (2002) · Thyroid · doi:10.1089/105072502760143935 · Cited by 71 · see citing works

Synthesis and Biological Evaluation of a Series of Liver-Selective Phosphonic Acid Thyroid Hormone Receptor Agonists and Their Prodrugs

Boyer, S. H., Jiang, H., Jacintho, J. D., Reddy, M. V., Li, H., Li, W., Godwin, J. L., SCHULZ, W. G., Cable, E. E., Hou, J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800824d · Cited by 66 · see citing works

Reaction of Phenolic Mannich Base Methiodides and Oxides with Various Nucleophiles

Gardner, P. D., Rafsanjani, H. S., & Rand, L. (1959) · Journal of the American Chemical Society · doi:10.1021/ja01522a052 · Cited by 62 · see citing works

Selective Thyromimetics Using Receptor and Tissue Selectivity Approaches: Prospects for Dyslipidemia

Joharapurkar, A. A., Dhote, V. V., & Jain, M. R. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2004706 · Cited by 58 · see citing works

Structural Determinants of Selective Thyromimetics

Yoshihara, H. A. I., Apriletti, J. W., Baxter, J. D., & Scanlan, T. S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0301181 · Cited by 39 · see citing works

Synthesis of thyroid hormone analogues. Part 3. Iodonium salt approaches to SK&F L-94901

Hickey, D. M. B., Leeson, P. D., Novelli, R., Shah, V. P., Burpitt, B. E., Crawford, L. P., Davies, B. J., Mitchell, M. B., Pancholi, K. D., Tuddenham, D., et al. (1988) · Journal of the Chemical Society Perkin Transactions 1 · doi:10.1039/p19880003103 · Cited by 27 · see citing works

PYRIDAZINE DERIVATIVES. XXIV.[1] EFFICIENTN-METHYLATION OF DIVERSELY SUBSTITUTED 3(2H)-PYRIDAZINONES USINGN,N-DIMETHYLFORMAMIDE DIMETHYLACETAL

Sotelo, E., & Raviña, E. (2002) · Synthetic Communications · doi:10.1081/scc-120004258 · Cited by 17 · see citing works

Benzylimidazolines as h5-HT1B/1D Serotonin Receptor Ligands: A Structure−Affinity Investigation

Law, H., Dukat, M., Teitler, M., Lee, D. K. H., Mazzocco, L., Kamboj, R., Rampersad, V., Prisinzano, T. E., & Glennon, R. A. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970513p · Cited by 16 · see citing works

HOMOLYTIC ALKYLATIONS OF 3, 6-DICHLOROPYRIDAZINE

Samaritoni, J. G. (1988) · Organic Preparations and Procedures International · doi:10.1080/00304948809355798 · Cited by 13 · see citing works

Anticoccidial derivatives of 6-azauracil. 5. Potentiation by benzophenone side chains

CARROLL, R. D., Miller, M. W., Mylari, B. L., Chappel, L. R., Howes, H. L., Lynch, M. J., Lynch, J. E., Gupta, S. K., Rash, J. J., & Koch, R. C. (1983) · Journal of Medicinal Chemistry · doi:10.1021/jm00355a019 · Cited by 9 · see citing works

Cardiac Specific Effects of Thyroid Hormone Analogues

Danzi, S. E., & Klein, I. L. (2011) · Hormone and Metabolic Research · doi:10.1055/s-0031-1291177 · Cited by 5 · see citing works

Computer-aided drug design: a practical guide to protein-structure-based modeling

Reynolds, C. H. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511730412.014 · Cited by 4 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works

A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis

Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084 · see citing works

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802 · see citing works

Direct effects of thyroid hormones on hepatic lipid metabolism

Sinha, R. A., Singh, B. K., & Yen, P. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.10 · Cited by 665 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works

Resmetirom: First Approval

Keam, S. J. (2024) · Drugs · doi:10.1007/s40265-024-02045-0 · Cited by 378 · see citing works

Current treatment paradigms and emerging therapies for NAFLD/NASH

Raza, S. (2020) · Frontiers in bioscience · doi:10.2741/4892 · Cited by 323 · see citing works

Therapeutic pipeline in nonalcoholic steatohepatitis

Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00408-y · Cited by 278 · see citing works

Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management

Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228 · see citing works

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Harrison, S. A., Bashir, M., Moussa, S. E., McCarty, K., Pablo Frias, J., Taub, R., & Alkhouri, N. (2021) · Hepatology Communications · doi:10.1002/hep4.1657 · Cited by 197 · see citing works

Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis

Kim, D., Kim, W., Joo, S. K., Bae, J. M., Kim, J. H., & Ahmed, A. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.08.014 · Cited by 191 · see citing works

Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease

Finan, B., Clemmensen, C., Zhu, Z., Stemmer, K., Gauthier, K., Müller, L., De Angelis, M., Moreth, K., Neff, F., Perez-Tilve, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.014 · Cited by 191 · see citing works

The first MASH drug therapy on the horizon: Current perspectives of resmetirom

Petta, S., Targher, G., Romeo, S., Pajvani, U. B., Zheng, M., Aghemo, A., & Valenti, L. (2024) · Liver international (Print) · doi:10.1111/liv.15930 · Cited by 174 · see citing works

Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges

Kokkorakis, M., Boutari, C., Hill, M. A., Kotsis, V., Loomba, R., Sanyal, A. J., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155835 · Cited by 155 · see citing works

Metabolic Targets in Nonalcoholic Fatty Liver Disease

Esler, W. P., & Bence, K. K. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.007 · Cited by 142 · see citing works

Activation of thyroid hormone receptor‐β improved disease activity and metabolism independent of body weight in a mouse model of non‐alcoholic steatohepatitis and fibrosis

Kannt, A., Wohlfart, P., Madsen, A. N., Veidal, S. S., Feigh, M., & Schmoll, D. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15427 · Cited by 140 · see citing works

Resmetirom: An Orally Administered, Small-molecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

Karim, G., & Bansal, M. B. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.60 · Cited by 145 · see citing works

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis

Pοlyzos, S. A., Kang, E. S., Boutari, C., Rhee, E., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154203 · Cited by 139 · see citing works

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease

Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 126 · see citing works

Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders

Saponaro, F., Sestito, S., Runfola, M., Rapposelli, S., & Chiellini, G. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00331 · Cited by 124 · see citing works

Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis

Finck, B. N. (2018) · Diabetes · doi:10.2337/dbi18-0024 · Cited by 125 · see citing works

Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease

Chen, Z., Yu, Y., Cai, J., & Li, H. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.08.006 · Cited by 125 · see citing works

Thyroid hormone receptor-β analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)

Ratziu, V., Scanlan, T. S., & Bruinstroop, E. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.018 · Cited by 117 · see citing works

Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease

Li, A. A., Ahmed, A., & Kim, D. (2019) · Gut and Liver · doi:10.5009/gnl19069 · Cited by 108 · see citing works

Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment

Byrne, C. D., Armandi, A., Pellegrinelli, V., Vidal‐Puig, A., & Bugianesi, E. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01045-z · Cited by 109 · see citing works

The therapeutic journey of pyridazinone

Akhtar, W., Shaquiquzzaman, M., Akhter, M., Verma, G., Khan, M. F., & Alam, M. M. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.07.061 · Cited by 98 · see citing works

Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liver-related diseases

Chi, H., Tsai, C., Tsai, M.-M., Yeh, C., & Lin, K. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0517-x · Cited by 94 · see citing works

Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis

Harrison, S. A., Ratziu, V., Anstee, Q. M., Noureddin, M., Sanyal, A. J., Schattenberg, J. M., Bédossa, P., Bashir, M. R., Schneider, D., Taub, R. A., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17734 · Cited by 94 · see citing works

New drugs for NAFLD: lessons from basic models to the clinic

Reimer, K. C., Wree, A., Roderburg, C., & Tacke, F. (2019) · Hepatology International · doi:10.1007/s12072-019-10001-4 · Cited by 83 · see citing works

The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases

Münte, E., & Hartmann, P. (2025) · Biomolecules · doi:10.3390/biom15040469 · Cited by 83 · see citing works

TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD

Caddeo, A. M., Kowalik, M. A., Serra, M., Runfola, M., Bacci, A., Rapposelli, S., Columbano, A., & Perra, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313105 · Cited by 78 · see citing works

Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development

Li, T., & Chiang, J. Y. L. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000978 · Cited by 77 · see citing works

Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)

Luong, X. G., Stevens, S., Jekle, A., Lin, T., Gupta, K., Misner, D., Chanda, S. M., Mukherjee, S., Williams, C., Stoycheva, A. D., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240338 · Cited by 77 · see citing works

Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies

Kokkorakis, M., Muzurović, E. M., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 77 · see citing works

Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids

Zhang, Y., Xie, R., Dai, C.-S., Gao, H., Zhou, G., Qi, T., Wang, W.-Y., Wang, H., & Yi-min, C. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.008 · Cited by 77 · see citing works

Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options

Tănase, D. M., Gosav, E. M., Neculae, E., Costea, C. F., Ciocoiu, M., Hurjui, L. L., Tărniceriu, C. C., & Floria, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165927 · Cited by 66 · see citing works

Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis

Suvarna, R., Shetty, S., & Pappachan, J. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-70242-8 · Cited by 66 · see citing works

Cascade reactions of nitrogen-substituted isocyanates: a new tool in heterocyclic chemistry

Vincent-Rocan, J.-F., Ivanovich, R. A., Clavette, C., Leckett, K., Bejjani, J., & Beauchemin, A. M. (2015) · Chemical Science · doi:10.1039/c5sc03197d · Cited by 64 · see citing works

Discovery of Highly Potent and Selective Thyroid Hormone Receptor β Agonists for the Treatment of Nonalcoholic Steatohepatitis

Hu, L., Gu, Y., Liang, J., Ning, M., Yang, J., Zhang, Y., Qu, H. Y., Yang, Y., Leng, Y., & Zhou, B. N. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01669 · Cited by 63 · see citing works

Thyroid Hormones, Thyromimetics and Their Metabolites in the Treatment of Liver Disease

Kowalik, M. A., Columbano, A., & Perra, A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00382 · Cited by 63 · see citing works

Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies

Zhang, C., Zhou, B.-G., Sheng, J., Chen, Y., Cao, Y.-Q., & Chen, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104984 · Cited by 62 · see citing works

A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia

Zhou, J., Waskowicz, L. R., Lim, A., Liao, X.-H., Lian, B., Masamune, H., Refetoff, S., Tran, B., Koeberl, D. D., & Yen, P. M. (2019) · Thyroid® · doi:10.1089/thy.2019.0007 · Cited by 60 · see citing works

Highlights on U.S. FDA-approved halogen-containing drugs in 2024

Ali, S., Tian, X., Meccia, S. A., & Zhou, J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117380 · Cited by 63 · see citing works

Thyroid hormone action and liver disease, a complex interplay

Marino, L., Kim, A., Ni, B., & Celi, F. S. (2023) · Hepatology · doi:10.1097/hep.0000000000000551 · Cited by 45 · see citing works

MASLD treatment—a shift in the paradigm is imminent

Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51 · see citing works

Understanding the Relationship between Nonalcoholic Fatty Liver Disease and Thyroid Disease

Vidal‐Cevallos, P., Gall, S. M.-B., Uribe, M., & Chávez-Tapia, N. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914605 · Cited by 51 · see citing works

Cell-Specific Transport and Thyroid Hormone Receptor Isoform Selectivity Account for Hepatocyte-Targeted Thyromimetic Action of MGL-3196

Hönes, G. S., Sivakumar, R. G., Hoppe, C., König, J., Führer, D., & Moeller, L. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213714 · Cited by 50 · see citing works

Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease

Wijarnpreecha, K., Aby, E. S., Ahmed, A., & Kim, D. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0239 · Cited by 49 · see citing works

Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist

Li, Q., Yao, B., Zhao, S., Lu, Z., Zhang, Y., Xiang, Q., Wu, X., Yu, H., Zhang, C., Li, J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00144 · Cited by 46 · see citing works

Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis

Wong, V. W., & Singal, A. K. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.06.06 · Cited by 45 · see citing works

Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis

Wirth, E. K., Puengel, T., Spranger, J., & Tacke, F. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2110864 · Cited by 42 · see citing works

Thyroid Hormone Receptor-β Agonists in NAFLD Therapy: Possibilities and Challenges

Li, L., Song, Y., Shi, Y., & Sun, L. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad072 · Cited by 45 · see citing works

Rezdiffra™ (resmetirom): a THR-β agonist for non-alcoholic steatohepatitis

Brisnovali, N. F., Haney, C., & Goedeke, L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.08.009 · Cited by 44 · see citing works

Potential use of TG68 - A novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis

Caddeo, A. M., Serra, M., Sedda, F., Bacci, A., Manera, C., Rapposelli, S., Columbano, A., Perra, A., & Kowalik, M. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1127517 · Cited by 43 · see citing works

New FDA drug approvals for 2024: Synthesis and clinical application

Wang, Y., Yang, F., Wang, B., Xie, L., & Chen, W. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117241 · Cited by 38 · see citing works

Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis

Li, W., Alazawi, W., & Loomba, R. S. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00260-2 · Cited by 43 · see citing works

Impact of NAFLD and its pharmacotherapy on lipid profile and CVD

Wang, Z., Ye, M., Zhang, X., Zhang, P., Cai, J., Li, H., & She, Z. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.07.010 · Cited by 37 · see citing works

Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH

Vandyck, K., McGowan, D. C., Luong, X. G., Stevens, S., Jekle, A., Gupta, K., Misner, D., Chanda, S. M., Serebryany, V., Welch, M. J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01029 · Cited by 36 · see citing works

Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated steatotic liver disease.

Wang, S.-D., Yin, J., Liu, Z., Liu, X., Tian, G., Xin, X., Qin, Y., & Feng, X.-J. (2024) · Life Science · doi:10.1016/j.lfs.2024.123211 · Cited by 43 · see citing works

Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis

Dutta, D., Kamrul-Hasan, A. B. M., Mondal, E., Nagendra, L., Joshi, A., & Bhattacharya, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.04.016 · Cited by 35 · see citing works

Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom

Kuchay, M. S., Isaacs, S. D., & Misra, A. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103034 · Cited by 34 · see citing works

Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges

Elbers, L. P. B., Kastelein, J. J. P., & Sjouke, B. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0564-7 · Cited by 34 · see citing works

Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease

Zhao, M., Xie, H., Shan, H., Zheng, Z., Li, G., Li, M., & Hong, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031102 · Cited by 32 · see citing works

Obesity disrupts the pituitary-hepatic UPR communication leading to NAFLD progression

Qian, Q., Li, M., Zhang, Z., Davis, S. W., Rahmouni, K., Norris, A. W., Cao, H., Ding, W., Hotamışlıgil, G. S., & Yang, L. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.014 · Cited by 32 · see citing works

Hepatic thyroid hormone receptor‐β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction‐associated steatohepatitis

Polyzos, S. A., & Targher, G. (2024) · Diabetes, obesity and metabolism · doi:10.1111/dom.16117 · Cited by 31 · see citing works

Thyroid hormone receptor alpha modulates fibrogenesis in hepatic stellate cells

Manka, P., Coombes, J., Sydor, S., Swiderska-Syn, M., Best, J., Gauthier, K., van Grunsven, L. V., Oo, Y., Wang, C., Diehl, A., et al. (2023) · Liver international (Print) · doi:10.1111/liv.15759 · Cited by 29 · see citing works

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial

Noureddin, M., Rinella, M. E., Taub, R. A., Labriola, D., Camacho, R. C., Alkhouri, N., Loomba, R. S., & Bansal, M. B. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70382 · Cited by 33 · see citing works

Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia

Jakobsson, T., Vedin, L., & Parini, P. (2017) · Drugs · doi:10.1007/s40265-017-0791-4 · Cited by 31 · see citing works

Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review

Guirguis, E. H., Grace, Y., Bolson, A., DellaVecchia, M. J., & Ruble, M. J. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2489 · Cited by 30 · see citing works

Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?

Arvanitakis, K., Koufakis, T., Cholongitas, Ε., Francque, S., & Germanidis, G. S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108811 · Cited by 31 · see citing works

A new mechanism of thyroid hormone receptor β agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles

Sun, K., Zhu, N.-L., Huang, S., Qu, H. Y., Gu, Y., Li, Q., Liu, J., & Leng, Y. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01303-x · Cited by 27 · see citing works

Therapeutic siRNA targeting PLIN2 ameliorates steatosis, inflammation, and fibrosis in steatotic liver disease models

Wang, Y., Zhou, J., Yang, Q., Li, X., Qiu, Y., Zhang, Y., Liu, M., & Zhu, A. J. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100635 · Cited by 27 · see citing works

TRβ activation confers AT2-to-AT1 cell differentiation and anti-fibrosis during lung repair via KLF2 and CEBPA

Pan, X., Wang, L., Yang, J., Li, Y., Xu, M., Liang, C., Liu, L., Li, Z., Xia, C., Pang, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52827-z · Cited by 27 · see citing works

Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD

Dibba, P., Li, A. A., Perumpail, B. J., John, N., Sallam, S., Shah, N. D., Kwong, W., Cholankeril, G. T., Kim, D., & Ahmed, A. (2018) · Diseases · doi:10.3390/diseases6030083 · Cited by 27 · see citing works

Thyroid hormone resistance: mechanisms and therapeutic development

Yao, B., Yang, C., Pan, C., & Li, Y. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111679 · Cited by 26 · see citing works

Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment

Chen, M., Cai, J., Yu, Y., She, Z., & Li, H. (2019) · Gene Expression · doi:10.3727/105221619x15536120524171 · Cited by 26 · see citing works

Receptor modulators associated with the hypothalamus -pituitary-thyroid axis

Cheng, X., Zhang, H., Guan, S., Zhao, Q., & Shan, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1291856 · Cited by 26 · see citing works

Main Factors Involved in Thyroid Hormone Action

Tedeschi, L., Vassalle, C., Iervasi, G., & Sabatino, L. (2021) · Molecules · doi:10.3390/molecules26237337 · Cited by 25 · see citing works

Targeting Thyroid Hormone/Thyroid Hormone Receptor Axis: An Attractive Therapy Strategy in Liver Diseases

Tang, Q.-Y., Zeng, M.-J., Chen, L., & Fu, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.871100 · Cited by 30 · see citing works

Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia

Hovingh, G. K., Klausen, I. C., Heggen, E., McCarty, K., Zhou, R., Isaac, B. F., Taub, R. A., Langslet, G., & Kastelein, J. J. P. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.01.023 · Cited by 24 · see citing works

Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials

Chen, J. Y. S., Chua, D., Lim, C. O., Ho, W. X., & Tan, N. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010158 · Cited by 23 · see citing works

Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future

Delitala, A. P., Delitala, G., Sioni, P., & Fanciulli, G. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1330259 · Cited by 29 · see citing works

Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease

Liao, C., Huang, P.-S., Chien, H., Lin, T.-K., Yeh, C., & Lin, K. (2022) · Biomedicines · doi:10.3390/biomedicines10061232 · Cited by 21 · see citing works

Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities

Amorim, R., Soares, P., Chavarria, D., Benfeito, S., Cagide, F., Teixeira, J., Oliveira, P. J., & Borges, F. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116723 · Cited by 21 · see citing works

Drug discovery targeting thyroid hormone receptor β (THRβ) for the treatment of liver diseases and other medical indications

Wang, K., Chen, F., Wang, J., & Liu, H. S. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.07.025 · Cited by 21 · see citing works

Lactobacillus delbrueckii subsp. lactis CKDB001 Ameliorates Metabolic Complications in High-Fat Diet-Induced Obese Mice

Jang, H., Joung, H., Chu, J., Cho, M., Kim, Y.-W., Kim, K. H., Shin, C. H., Lee, J., & Ha, J. (2024) · Nutrients · doi:10.3390/nu16244260 · Cited by 20 · see citing works

Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis

Bhushan, S. R., Sohal, A., Noureddin, M., & Kowdley, K. V. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2478917 · Cited by 20 · see citing works

Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation/accessibility of Resmetirom

Brennan, P., Kopka, C. J., Agirre‐Garrido, L., Hansen, C. D., Alkhouri, N., Schattenberg, J. M., Wajcman, D. I., Isaacs, S. D., Michel, M. S., & Lazarus, J. V. (2025) · npj gut and liver. · doi:10.1038/s44355-024-00017-5 · Cited by 21 · see citing works

Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024

Wang, Z., Sun, X., Sun, M., Wang, C., & Yang, L. (2025) · Pharmaceuticals · doi:10.3390/ph18050729 · Cited by 18 · see citing works

Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)

Alkhouri, N. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1708899 · Cited by 18 · see citing works

Implementing sustainable liver health in Europe: a second EASL–Lancet Commission

Karlsen, T. H., Hutchinson, S. J., Zelber‐Sagi, S., Carrieri, P., Negro, F., Lim, A. G., Cecchini, M., Dirac, M. A., Murray, F., Engebretsen, E., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00138-8 · Cited by 17 · see citing works

Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults

Ogawa, Y., Yoneda, M., Kobayashi, T., Honda, Y., Kessoku, T., Imajo, K., Saito, S., & Nakajima, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1543403 · Cited by 17 · see citing works

Association between hypothyroidism and liver fibrosis risk: a systematic review and meta-analysis

Rahadini, A. A. D., & Rahadina, A. (2022) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2022.118594 · Cited by 17 · see citing works

Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease

Chui, Z. S. W., Xue, Y.-Q., & Xu, A.-M. (2024) · Medical Review · doi:10.1515/mr-2024-0007 · Cited by 18 · see citing works

Thyromimetics and MASLD: Unveiling the Novel Molecules Beyond Resmetirom

Ezhilarasan, D. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16874 · Cited by 17 · see citing works

New drug therapies for metabolic dysfunction-associated steatohepatitis

Chiang, J. Y. L. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.001 · Cited by 16 · see citing works

Lipid Hormones at the Intersection of Metabolic Imbalances and Endocrine Disorders

Dobre, M.-Z., Vîrgolici, B., & Cioarca-Nedelcu, R. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47070565 · Cited by 17 · see citing works

Sex and gender differences in MASLD: pathophysiological mechanisms, clinical implications, and future directions

Jamalinia, M., Saeian, S., Nikkhoo, N., Nazerian, A., & Lankarani, K. B. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.131 · Cited by 16 · see citing works

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH

Finan, B., Parlee, S. D., & Yang, B. S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101153 · Cited by 16 · see citing works

Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier

Tiwari, A., Sharma, A., Kumar, H., Gupta, V., Deshpande, V., Mupparaju, J. S., Mishra, T., Bharadwaj, H., Dahiya, D., & Jain, V. (2025) · Biomedicines · doi:10.3390/biomedicines13092079 · Cited by 19 · see citing works

Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist

Taub, R. A., Chiang, E., Chabot-Blanchet, M., Kelly, M. J., Reeves, R. A., Guertin, M., & Tardif, J. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.056 · Cited by 164 · see citing works

Cell-Specific Transport and Thyroid Hormone Receptor Isoform Selectivity Account for Hepatocyte-Targeted Thyromimetic Action of MGL-3196

Hönes, G. S., Sivakumar, R. G., Hoppe, C., König, J., Führer, D., & Moeller, L. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213714 · Cited by 50 · see citing works

P5387LDL cholesterol, apolipoprotein B, lipoprotein(a), apolipoprotein CIII and triglyceride lowering by MGL-3196, a thyroid hormone beta selective agonist, in a 12 week study in HeFH patients

Kastelein, J. J. P., Klausen, I. C., Hovingh, G. K., Heggen, E., Taub, R. A., & Langslet, G. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy566.p5387

Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index

Erion, M. D., Cable, E. E., Ito, B. R., Jiang, H., Fujitaki, J. M., Finn, P. D., Zhang, B., Hou, J., Boyer, S. H., van Poelje, P. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702759104 · Cited by 273 · see citing works

Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH

Vandyck, K., McGowan, D. C., Luong, X. G., Stevens, S., Jekle, A., Gupta, K., Misner, D., Chanda, S. M., Serebryany, V., Welch, M. J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01029 · Cited by 36 · see citing works